Publications by authors named "E Kahler"
Objective: Oral, low-dose and ultra-low-dose continuous combined 17β-estradiol (E) plus dydrogesterone (D) reduce vasomotor symptoms (VMS) in postmenopausal women.
Methods: Two phase 3, double-blind studies were included. In the European study, postmenopausal women were randomized 2:1:2 to receive E0.
Objectives: Evidence suggests ethnicity-specific differences in postmenopausal symptoms, highlighting the need for therapies that are efficacious across different ethnicities. We evaluated the efficacy of an ultra-low dose combination of 0.5 mg estradiol and 0.
View Article and Find Full Text PDFIntroduction: Brachycephalic obstructive airway syndrome (BOAS) is a common condition in brachycephalic dogs, with Pugs (PG) and French Bulldogs (FB) appearing to be particularly typically affected. Objective and easy-to-perform tests are necessary to detect the disease at an early stage and to exclude dogs affected by BOAS from breeding.
Methods: The present study investigated the extent to which vital signs and salivary cortisol concentrations can be used to distinguish between healthy and BOAS-affected dogs in a standardized fitness test.
Objective: Among postmenopausal women, oral, ultra-low-dose continuous combined estradiol (E0.5 mg) plus dydrogesterone (D2.5 mg) reduces vasomotor symptoms (VMS).
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the safety and tolerability of ultra-low dose estradiol and dydrogesterone among postmenopausal women using data from three clinical trials.
- A total of 1027 participants were analyzed, revealing that the rates of treatment-emergent adverse events (TEAEs) were comparable between the treatment (E0.5/D2.5 mg) and placebo groups.
- While the treatment group saw a higher incidence of breast pain and uterine hemorrhage, the overall conclusion was that the ultra-low dose combination was well tolerated without significant increases in adverse events compared to placebo.